US FDA Drug Risk Management Board To Be Lead By CDER Deputy Cavazzoni
CDER Director Woodcock announced that the drug center will soon launch the Drug Risk Management Board, which will coordinate product safety activities among the different offices; Patrizia Cavazzoni, who serves as CDER's deputy director of operations, will chair the board.
You may also be interested in...
Postmarket Safety Signal Evaluation: US FDA ‘MAPPS’ Out New Approach
For drug sponsors, FDA's revised process could mean more public disclosures about potential safety risks and more regulatory actions to address those risks. CDER seeks to better leverage scientific and regulatory expertise, including in product quality and compliance, in investigating safety signals under the new policy manual, which also includes target timelines for action.
Big Tech Helping US FDA With Sentinel Expansion
Amazon, Microsoft, IBM among those helping build new operations and innovation centers for the US FDA's safety surveillance system.
New CDER No. 2 May Impact FDA's Safety Monitoring Aspirations
Patrizia Cavazzoni, CDER's new deputy director for operations, has safety surveillance background and wants to see FDA continue to grow its capabilities.